What is the new FDA approval for the libido pill Addyi?

The FDA has expanded the approval of Addyi to include women over 65 who have gone through menopause.

What are the risks of taking the drug Addyi?

Addyi has a safety warning about dangers, including dangerously low blood pressure and fainting, when combined with alcohol.

What condition does Addyi treat in women?

Addyi treats hypoactive sexual desire disorder, a condition of troublingly low sexual appetite in women.

Home / Health / FDA Expands Libido Pill Access Post-Menopause

FDA Expands Libido Pill Access Post-Menopause

16 Dec, 2025

•

Summary

FDA broadens Addyi's use to women over 65 post-menopause.
Addyi carries a warning for dangerous interactions with alcohol.
Low libido drug development surged after Viagra's success.

FDA Expands Libido Pill Access Post-Menopause

U.S. health officials have expanded the approval of Addyi, a medication designed to boost libido in women. The Food and Drug Administration announced that the once-daily pill can now be prescribed to women over the age of 65 who have completed menopause. This decision broadens the accessibility of the drug, which was first approved a decade ago for premenopausal women experiencing emotional distress due to low sex drive.

Addyi, marketed by Sprout Pharmaceuticals, was initially anticipated to be a major success in women's health. However, its limited sales can be attributed to notable side effects like dizziness and nausea. Critically, the drug carries a serious safety warning regarding the consumption of alcohol, which can lead to dangerously low blood pressure and fainting. This cautionary note underscores the complex safety profile of the medication.